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Introduction
On October 22 and 23, 2007, the National Cancer Insti-
tute (NCI) hosted "The NCI Thyroid Fine Needle Aspira-
tion (FNA) State of the Science Conference," a two-day
gathering in Bethesda, Maryland. Its mission was to estab-
lish a comprehensive interdisciplinary informational dia-
logue dedicated to thyroid FNA. Preparations for the
conference began 18 months earlier with the designation
of a steering committee, the appointment of nine working
committees, coordination with co-sponsoring organiza-
tions, and the establishment of a dedicated permanent
web site. The function of the website was to serve as a per-
manent educational tool for health care practitioners and
patients alike, as well as to foster on-line dialogue.
Six committees were charged with preparing summary
documents based on literature reviews on the following
subjects: 1. Indications/Pre-FNA requirements; 2. Training
and Credentialing; 3. Technique; 4. Terminology and
Morphologic Criteria; 5. Ancillary Studies; and 6. Post-
FNA Options for Testing and Treatment. Three additional
committees were formed, one each to oversee the website,
publications ensuing from the conference and the estab-
lishment of an on-line educational cytopathology atlas.
Literature reviews were limited to English language publi-
cations dating back to 1995, using PubMed as the search
engine, with key words determined by the committee
members. The first draft of the committees' summary doc-
uments ("Review and Conclusions") was posted on the
web site and open for on-line forum discussion from May
1-June 30, 2007. There were several subsequent drafts and
on-line discussion periods (Aug 15 – Sept. 30, 2007 and
Nov. 30-Dec. 15, 2007). The documents underwent revi-
sion after each comment period prior to re-posting on the
web. The two-day "live" conference in October, attended
by 154 registrants, comprised of pathologists, endocrinol-
ogists, surgeons, and radiologists, gave the committees an
in-depth opportunity to present their conclusions and
debate controversial areas.
This is an abridged version of the topics reviewed at the
conference and the website. This is not a "standards of
practice" guideline, nor is it endorsed as such by the
National Cancer Institute.
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I. Indications for Thyroid FNA and Pre-FNA 
Requirements
A. Indications for performing an FNA of a thyroid nodule 
discovered by palpation
Every patient with a palpable thyroid nodule is a candi-
date for fine needle aspiration (FNA) and should undergo
further evaluation to determine if an FNA is war-
ranted[1]Thyroid nodules detected by palpation are usu-
ally at least 1.0 cm in dimension and are therefore
clinically significant. Before a decision is made to perform
an FNA, a complete history should be taken; a physical
examination directed to the thyroid gland and cervical
lymph nodes should be performed; and a serum thyrotro-
pin level (TSH) and thyroid ultrasound (US) should be
obtained [1,2].
Patients with a normal or elevated serum TSH level should
proceed to a thyroid US to determine if an FNA needs to
be performed (see section B below); those with a
depressed serum TSH should have a radionuclide thyroid
scan, the results of which should be correlated with the
sonographic findings [1,2]. Functioning thyroid nodules
in the absence of significant clinical findings do not
require an FNA because the incidence of malignancy is
exceedingly low [3]. A nodule that appears either iso- or
hypo-functioning on radionuclide scan, however, should
be considered for FNA based on US findings (see section
B below) [1].
B. Indications for performing an FNA of a thyroid nodule 
discovered via imaging
A nodule not previously suspected or discovered clini-
cally, but detected by an imaging study, is considered an
incidental nodule ("incidentaloma"). Incidentalomas
detected by 18FDG-PET are unusual (2–3% of all PET
scans) but have a higher risk of cancer (14–50%) com-
pared to background incidence [4]. Therefore, a focal nod-
ule that is 18FDG-PET-avid is an indication for FNA. This
applies only to focal lesions. Diffuse increased uptake on
18FDG-PET does not warrant FNA unless thyroid sonogra-
phy detects a discrete nodule.
All focal hot nodules detected on sestamibi scans and con-
firmed by US to be a discrete nodule should undergo FNA.
Thyroid incidentalomas detected on sestamibi scans have
a higher risk of cancer (22–66%) compared to baseline
risk [5,6].
Incidentalomas detected by US (e.g., carotid Doppler
scans or scans done for parathyroid disease) have a cancer
risk of approximately 10–15% (0–29%) and should
undergo dedicated thyroid sonographic evaluation [7-
12]. Lesions with a maximum diameter greater than 1.0–
1.5 cm should be considered for biopsy unless they are
simple cysts or septated cysts with no solid elements. FNA
may also occasionally be replaced by periodic follow-up
for nodules of borderline size (between 1.0 and 1.5 cm in
maximum diameter) if they have sonographic features
that are strongly associated with benign cytology.
A nodule of any size with sonographically suspicious fea-
tures can also be considered for FNA. Sonographically sus-
picious features include microcalcifications, hypoechoic
solid nodules, irregular/lobulated margins, intra-nodular
vascularity, and nodal metastases (or signs of extracapsu-
lar spread). This latter recommendation is controversial
because it includes patients with microcarcinomas, in
whom a survival benefit following an FNA diagnosis has
not been documented. Nevertheless, the American Thy-
roid Association, the Academy of Clinical Thyroidologists
and a collaborative effort of the American Association of
Clinical Endocrinologists and the Associazione Medici
Endocrinologi make this recommendation [1,7,13].
There are few direct data on the cancer risk of thyroid inci-
dentalomas detected by computed tomography (CT) or
magnetic resonance imaging (MRI). They are seen in at
least 16% of patients evaluated by neck CT or MRI [14].
The risk of cancer in one study was predicted at 10%, but
it included only a limited number of patients who went
on to FNA[15]. CT and MRI features can not determine
the risk of malignancy, except in very advanced cases that
are unlikely to be incidental. Until more data are availa-
ble, incidentalomas seen on CT or MRI should undergo
dedicated thyroid sonographic evaluation. Any nodule
with sonographically suspicious features (see above)
should be considered for FNA. In addition, lesions that
have a maximum diameter greater than 1.0–1.5 cm
should also be considered for FNA (see above).
C. Indications for performing a thyroid FNA using 
palpation vs. ultrasound for guidance
In the evaluation of individual patients with nodular dis-
ease, there are occasions when either palpation or ultra-
sound-guided (US-guided) FNA of a thyroid nodule are
reasonable to perform. Palpation-guided FNA can be per-
formed with high levels of success in specific circum-
stances [16-18]. The benefits of palpation-guided FNA of
thyroid nodules are its reduced cost in comparison to US-
guided FNA as well as its logistical efficiency: the practi-
tioner can perform the procedure without an US machine
or assistance from other practitioners.
Published data from one study concludes that US evalua-
tion changes the management of 63% of patients with
palpable thyroid nodules [19]. US findings like irregular
margins, microcalcifications, intra-nodular vascularity
and the characteristics of other occult thyroid nodules can
be used to identify nodules at risk that should be sampled
[12,20]. In several studies US guidance was shown toCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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reduce the rates of non-diagnostic (i.e., insufficient cells
and/or colloid) and false-negative aspirates [16,17,21].
Re-evaluation of patients using US-guided FNA for those
with initially benign results on palpation-guided FNA, led
to the reclassification of patients and the diagnosis of 14%
more cancers in one series [22]. Finally, there are US-spe-
cific findings that can be used to inform the results of the
US-guided FNA (e.g. the benign sonographic appearance
of a unilocular cyst explains why only cyst fluid was
obtained by FNA).
A palpation-guided FNA can be considered when a thy-
roid nodule >1 cm in maximum diameter has been con-
firmed via US examination of the thyroid. The
sonographic examination is important, because physical
examination can be imprecise in determining nodule size,
its origin from the thyroid rather than adjacent tissues,
and the degree of cystic change. US-guided FNA is accept-
able and is preferred for nodules that are not palpable,
>25% cystic or have been biopsied before and yielded a
non-diagnostic result [23,24].
D. The informed consent form for thyroid FNA
Legislation regulating the conditions under which con-
sent must be obtained vary greatly by state [25-27]. Thus,
providers (e.g., pathologists, radiologists, surgeons, endo-
crinologists, etc.) who perform thyroid FNA need to
design informed consent policies and forms based on
state regulations. For thyroid FNA, informed consent
materials, including written documents, if used, should
describe the FNA procedure and potential risks and com-
plications. The possibility of the most frequently occur-
ring complication, namely, hematoma, should be
mentioned. Information should be presented in a manner
to facilitate patient understanding. It might be useful to
mention the possibility of a non-contributory result. Esti-
mates of accuracy, such as false-negative and false-positive
proportions, are not mandatory and should be considered
only if the practitioner believes they would facilitate
patient comprehension.
E. Information required on the requisition form that 
accompanies a thyroid FNA
Federal regulations in the United States require that spe-
cific identifying information be provided to laboratories
with all specimens submitted for laboratory testing [28].
These include the name and address of the person request-
ing the test; the patient's name or unique identifier; the
patient's gender; the patient's age or date of birth; the
name of test to be performed; the specimen source; the
date of specimen collection; and any additional relevant
information. The purpose of this discussion is to consider
what 'additional relevant information' a laboratory needs
to properly evaluate a thyroid FNA specimen.
The location of the nodule (right vs. left; isthmus; upper
pole, mid-pole, lower pole, etc.) should be specified on
the requisition form to permit correlation with sono-
graphic findings and subsequent histopathologic exami-
nation (if any). Such identification is often necessary
because patients often present with multiple nodules
(some but not all of which may be biopsied), or they may
develop other nodules over time.
There is, at best, an imperfect correlation between the size
of a nodule and the likelihood of malignancy, but larger
nodules (>4 cm) may be associated with a higher malig-
nancy risk, and therefore size should be included [29].
Benign cytologic changes that mimic malignancy, particu-
larly papillary carcinoma, occur in some patients with
autoimmune (Hashimoto's) thyroiditis. If not alerted to
this history, a misdiagnosis can occur. Furthermore,
nuclear alterations may be seen in patients with a history
of I-131 therapy (for hyperthyroidism) or external radia-
tion [30]. In some patients with Graves' disease, an FNA
of a nodule may include pleomorphic cells from the extra-
nodular Graves' thyroid parenchyma that can be a pitfall
in cytologic interpretation [31].
It is important to note a personal history of malignancy
because metastatic tumors to the thyroid can mimic the
appearance of a primary thyroid neoplasm. Metastatic
renal cell carcinoma mimics a follicular neoplasm;
melanoma can mimic medullary carcinoma; metastatic
lung cancer can mimic anaplastic carcinoma of the thy-
roid. Cytologists should be alerted to the possibility of a
metastatic tumor in any patient with a history of malig-
nancy.
Approximately 15% of medullary thyroid cancers are
familial (familial MTC or MEN2a or 2b). Knowledge of
family history can alert the pathologist to the possibility
of medullary carcinoma. Recent data show that papillary
thyroid cancer can also be familial, and thus knowledge of
such family history can alert the pathologist to consider
papillary carcinoma.
Therefore, at a minimum, the following data should
appear on the requisition form that accompanies a thy-
roid FNA to the laboratory:
1. Usual required data for lab test submission (see above)
2. Location of the nodule
3. Estimated size of the nodule
4. History of hypothyroidism, autoimmune thyroiditis, or
a positive test for anti-thyroid antibodiesCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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5. History of Graves' disease
6. History of I131 or external radiation therapy, accompa-
nied by the dates of treatment
7. Personal history of cancer
8. Family history of thyroid cancer
The following information can be useful to the cytologist
but is considered optional on the requisition form: 1.
additional clinical history, e.g., that a prior FNA was done,
or that the patient is undergoing levothyroxine therapy.
Morphologic alterations due to a prior FNA can affect
cytologic interpretation, and levothyroxine use can alter
follicular cell morphology. 2. TSH level. If a patient has
Hashimoto's hypothyroidism or Graves' disease, cytologic
findings can be affected. A lower serum TSH level is also
associated with a lower risk of thyroid cancer. 3. results of
US examination. 4. results of nuclear medicine imaging
studies[32,33].
II. Training and Credentialing for the 
Performance of a Thyroid FNA
A. Training for the Performance of Thyroid FNA
Diagnostic accuracy of thyroid FNA is highly variable
[18,34-38]. The majority of diagnostic failures are due to
non-diagnostic samples or pathologists issuing diagnosis
on samples with inadequate material [39]. Efforts toward
improvement in proficiency in FNA sampling and speci-
men preparation should be given high priority. Reports
comparing the effectiveness of specific, defined training
strategies for FNA procurement are lacking and there is lit-
tle agreement on what the definition of adequate training
is. Merely performing a large number of FNAs does not
improve results when controlled for level of training[40].
There is, however, evidence that when FNA specimen pro-
curement is concentrated in fewer hands and when the
same physician both procures and microscopically exam-
ines the specimen, the results improve [41,42]. Training
in procurement has significant impact on results regard-
less of the method of guiding the needle (ie palpation vs.
ultrasound guidance). The consistent and timely feedback
on specimen quality provided to physicians who both
procure and examine specimens microscopically helps to
improve results as well. Ultrasound (US) guidance of the
sampling provides evidence that the needle is correctly
placed within the target.
Two reviews of FNA state that the procurement of the sam-
ples is not as easy as generally perceived and stress the
importance of obtaining an adequate sample in order for
the test to be useful [41,43]. Suen makes the recommen-
dation that "the procedure is carried out by a core group
of dedicated physicians" [44]. In a 2003 editorial Kocjan
discussed many of the problems associated with the cur-
rent practice of FNA and stressed the importance of train-
ing in specimen collection and preparation regardless of
the specialty of the operator[45].
A recent publication on the teaching of procedural skills
indicates that the most important factor for mastering
procedures is focused training with appropriate feedback
by expert practitioners [46]. The previously widely held
belief that simply performing a large number of proce-
dures produces excellence does not appear to be true [47].
Given these observations it doesn't make sense to advo-
cate that a specific number of procedures should be per-
formed without specifying the circumstances. Reports
comparing the effectiveness of specific, defined training
strategies for FNA sampling are lacking in the literature.
Such studies would be helpful in order to optimize train-
ing of operators in various settings and specialties.
In addition to the harvesting of diagnostic material, train-
ing for technical excellence in sample preparation cannot
be overemphasized. Several options are available for the
preparation and processing of FNA specimens. On-site
sample adequacy assessments are performed with smears
which may be stained with a modified Giemsa or a rapid
Papanicolaou technique. In order to optimize on-site ade-
quacy smears, appropriate training in smear technique is
imperative in any FNA training program regardless of spe-
cialty. On-site evaluation of the specimen adequacy has
lessened the percent unsatisfactory specimens and limited
the number of passes per nodule sampled [48-50]. In all
but one of these reports on-site evaluation of the speci-
mens was one of several factors reported to improve accu-
racy, but was not calculated as a separate factor [50]. One
report found on-site evaluation helpful in minimizing
unsatisfactory samples only for less experienced radiolo-
gists procuring samples [51]. At the very least, it appears
that on-site evaluation serves as an important educational
tool for the physician performing the FNA in providing
immediate feedback on the quality of the specimen.
Training in US imaging technique and interpretation is
beyond the scope of this review.
Components of FNA procurement training:
1. Studying of texts and DVD or similar teaching aids with
moving images that explain the principles and show all
required tasks including sampling and specimen prepara-
tion in detail. Lectures and demonstrations can also be
helpful. A detailed instructional video done by Dr. Britt-
Marie Ljung is available to all, sponsored by the Papanico-
laou Society of Cytopathology on their website under the
PSC Guidelines link.CytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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2. Bench practice of sampling and smearing on bovine
liver or similar safe material, under supervision. Timely
and precise placement of the needle tip under ultrasound
guidance can be practiced with a model (for example tur-
key breast with a "target" inserted between the muscles or
commercially available practice materials).
3. Sampling of thyroid nodules guided either by palpation
or US, supervised by a proficient operator, and followed
by examination of all samples to provide timely feed back
on quality of samples.
4. Number of cases needed for achieving proficiency will
vary depending on individual background and aptitude as
well as case mix. Although it is best to start with easier
cases, challenging cases need to be included. One should
expect at least 90% diagnostic specimens before training
is complete. The sampling of thyroid cysts devoid of fol-
licular cells designated as "cyst fluid only" and categorized
as " non-diagnostic" should not be considered "non-diag-
nostic" for credentialing purposes.
B. Credentialing and re-credentialing
Complete residency/fellowship training including FNA
procurement or equivalent training in an alternative set-
ting should suffice for initial credentialing.
For re-credentialing, documentation of the number of
total FNA procedures per year, for an individual provider,
in combination with a documented unsatisfactory sample
rate (<10%) is a conservative measure of proficiency. The
sampling of  thyroid cysts devoid of follicular cells desig-
nated as “cyst fluid only” and categorized as “ non-diag-
nostic” should not be considered “non-diagnostic” or
“unsatisfactory” for credentialing purposes. 
III. Techniques for the Performance of Thyroid 
FNA
A. Aspiration devices, needles and methods
A wide variety of needles of varying lengths and diameters
are available for FNA. Commonly available 27–22 g nee-
dles are best used for thyroid FNA with 25–27 g needles
being preferred for the initial biopsies and increasing nee-
dle size if needed; larger diameter needles are reserved for
drainage of viscous colloid cyst contents. A variety of
syringe holders are also available; among the oldest and
most widely used pistol grip-like holders is the Cameco
syringe gun. Other aspiration devices include the Tao
instrument and the Inrad aspiration biopsy syringe gun.
The native suction provided by surface tension within
smaller diameter needles often make devices for addi-
tional suction unnecessary [52]. When suction is needed,
such as in the drainage of cyst contents, the Zajdela tech-
nique can still be used by having a section of IV tubing
interposed between the needle held by the physician and
the aspiration device held by an assistant.
The basic principals of thyroid FNA are described in detail
elsewhere and are the same whether the needle is inserted
into the lesion using manual palpation or ultrasound
guidance [53]. As mentioned previously, a detailed
instructional video is available at the website of the
Papanicolaou Society of Cytopathology. When visualized
with ultrasound, different areas of large masses should be
sampled. If the nodule is complex, the wall, solid ele-
ments and suspicious calcified areas should be sampled
avoiding cystic areas. Cellular material is obtained by the
cutting action of the trailing edge of the needle (heel of
the bevel) and is retained in the needle core by forward
motion and capillary tension. As a starting point, a dwell
time of 2–5 seconds within the nodule with 3 forward and
back oscillations per second usually maximizes cellular
yield, minimizes bloody artifacts, and efficiently produces
1–2 slides per biopsy pass.
Easily learned and very effective smearing techniques
allow the aspirated material to be presented on the slides
for optimal fixation, staining, and microscopic assess-
ment [53]. Direct smears are necessary for immediate
assessment at the time of biopsy. The failure or any signif-
icant flaw in smearing technique can limit or totally
hinder microscopic evaluation, irrespective of how much
material is obtained during the biopsy. Poor smear train-
ing and other logistical issues with respect to specimen
transport to the laboratory have led to the utilization of a
secondary means of specimen preparation, liquid based
cytology (LBC), to be used in some laboratories [see spec-
imen processing below].
Currently, the ideal physician to perform thyroid FNA in
an institutional or office practice should be experienced,
having repeatedly demonstrated appropriate judgment in
nodule selection, technical excellence, and proficiency in
obtaining aspirate material and preparing slides. For ultra-
sound guidance of FNA for either non-palpable or palpa-
ble nodules, this physician must have high resolution
ultrasound imaging equipment with high frequency lin-
ear array transducers available, appropriate diagnostic
skills, and documented experience in performing ultra-
sound-guided FNA.
B. Anesthesia
Most thyroid FNAs are well-tolerated and are not associ-
ated with significant patient discomfort or pain; however,
the use of local anesthesia insures that the procedure will
not be painful, and offers peace of mind, resulting in an
overall more comfortable experience. For this reason, the
trend among many experienced FNA physicians is to use
local anesthesia for all thyroid FNAs[54]. However, localCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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anesthetic may cause difficulty in subsequent sample eval-
uation. For deep, non-palpable thyroid nodules that may
require more time and probing to reach the nodule, and
for all biopsies using needles other than a fine needle,
local anesthesia is recommended.
The local anesthetic of choice is 1% lidocaine or Lidocaine
2% Epi l:100,000. This may be performed through the
injection of about 0.5 cc of the anesthetic utilizing a long
bevel injection needle, (not a TB 27 g injector), slowly
into the subcutaneous fat (not the dermis) thus allowing
the anesthetic to back infiltrate the dermal nerves rather
than make a painful intradermal wheal.
C. Core biopsy
There is limited literature regarding the use of modern
biopsy needles, but so far it suggests that it is safe, well tol-
erated, and associated with a low incidence of complica-
tions. This is mainly due to the use of single action spring
activated needles, i.e. Temno needle, which utilizes a non-
advancing cutting action, or double action spring loaded
needles (i.e. Monopty or Biopty gun) with a short throw
device (11 mm excursion) [55,56].
FNA remains the best technique available to date for the
initial evaluation of thyroid nodules. The slight increase
in diagnostic accuracy obtained by CNB is outweighed by
ease of use, cost effectiveness, and less patient discomfort
associated with FNA [57]. Ultrasound-guided CNB should
not be seen as a competitor of FNA, but rather as a com-
plementary investigational tool. CNB under ultrasound
guidance utilizing modern needles may be advantageous
in cases rendered "unsatisfactory" by FNA, but offers no
additional diagnostic value in separating a cellular hyper-
plastic nodule from follicular adenoma and follicular car-
cinoma [57] When cytopathology expertise is not
available, CNB provides a small tissue sample for histo-
logic examination.
D. Preparation of FNA material for Routine Evaluation
Aspirated tissue or cyst fluid may be directly smeared for
air-dried and alcohol fixed preparations for staining with
Romanowsky (Diff-Quik, Wright-Geimsa, Wright stains)
and Papanicolaou stains, respectively. Direct smears can
be processed alone or with a supplemental LBC or cell-
block prepared. Likewise, liquid based processing can be
utilized either alone or as a supplement to direct smears.
Direct smears, however, are essential for immediate
assessment. For LBC, the aspiration needle should be
flushed with a small amount (~0.5 cc) of liquid (Cytolyt™,
balanced saline or Hank's solution) and placed in a Fal-
con tube for transport to the lab. For remote transport or
for specimens expected to have delayed processing, a fixa-
tive such as Preservcyt™ or CytoRich Red™ is necessary for
optimal cellular preservation. This cell-rich liquid can also
be used for cellblock preparation if needed. Residual cyst
fluid may be submitted to the lab fresh or fixed for further
processing, either by LBC or cellblock.
Immediate assessment is widely utilized. Some laborato-
ries employ it routinely for all thyroid FNAs as it may
decrease complications, improve triage of tissue and
determines sample adequacy [23,48,51,58-62]. One study
found that immediate assessment as currently practiced,
increases adequacy by up to 20%, but places a significant
cost and burden on the laboratory [63].
E. Optimal number of passes
It is not possible to define a specific number of passes that
should be used in every setting. Although studies show
that the more passes performed the higher the adequacy,
between 2 and 5 passes are a reasonable number of passes
to perform to try and ensure an adequate sample
[50,63,64]. There is no justification to recommend a dif-
ferent number of passes for a cystic lesion, unless the cri-
teria for adequacy are different. A reasonable protocol is as
follows: FNAs with rapid interpretation available: 2 biop-
sies from different areas of the lesion with a representative
slide stained for adequacy. No more tissue is needed if a
cyst is completely drained and no residual mass is identi-
fied, a specific malignancy is identified (and no ancillary
tests are deemed necessary), or if the aspirate appears ade-
quate. Additional biopsies are recommended if there is a
residual mass after draining a cyst, cellularity is inade-
quate or to enrich a sample for cellblock or ancillary stud-
ies.
For FNAs without a rapid interpretation available: 2–5
biopsies from different sites with representative tissue
from each pass smeared on a slide (or 2) and/or the tissue
rinsed into a collection tube for either LBC or cellblock
preparation.
F. Adequacy of Solid and Cystic lesions
Given that the purpose of thyroid FNA is to provide clini-
cally useful information regarding the need for surgery,
the FNA sample must be adequate enough for an interpre-
tation that yields a low false negative rate. A thyroid FNA
that is persistently inadequate may or may not result in
surgery, depending on the clinical and ultrasounographic
considerations [23,65].
Adequacy defines the quality and quantity of a sample, a
definition that varies not only with respect to the site sam-
pled, but also with respect to the type of lesion sampled.
The cellularity of a specimen is influenced by the intrinsic
nature of the lesion, and, as such, the same definition of
adequacy does not apply to all specimen types [66].CytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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All thyroid FNAs, however, must be technically adequate
with well-preserved and well-prepared tissue for interpre-
tation. Any cytological atypia precludes the interpretation
of an inadequate sample and, although adequacy may be
deemed "limited", an interpretation of "atypical" must be
rendered, preferably with an explanation of the atypia.
An interpretation of an inflammatory process such as thy-
roiditis does not require a minimum number of follicle
cells. An interpretation of a colloid nodule in which there
is abundant, thick colloid present does not require a min-
imum number of follicle cells [66-68]. In solid nodules
producing a follicular cell population with less than abun-
dant colloid, a minimum number of 5–6 groups with a
least 10 cells is recommended, preferably on a single slide
[50,69,70]. Thyroid cysts with little to no follicular cells
should be interpreted as "cyst fluid only" under the head-
ing "nondiagnostic" and not "unsatisfactory". An
optional recommendation for correlation with the cyst
size, complexity, and ultrasonographic character may be
added.
IV: Diagnostic terminology/classification scheme 
and morphologic criteria for cytologic diagnosis 
of thyroid lesions
A. Diagnostic terminology/classification scheme for thyroid 
fine-needle aspiration (FNA) interpretation
Several classification schemes have been suggested by var-
ious authors based on personal/institutional experiences
and clinical organizations [9,13,66,71-74]. A recent sur-
vey of pathologist and clinicians on the perceptions of
diagnostic terminology and cytopathology reporting of
thyroid FNA, showed a discord between pathologists and
clinicians[75].
Many studies favor a tiered system for classifying thyroid
FNA; this ranges from 3–6 (or more) diagnostic category
schemes. The most favored one is a six category diagnostic
scheme consisting of benign, lesion (atypia) of undeter-
mined significance, follicular neoplasm, suspicious,
malignant, and unsatisfactory [71-75]. A suggested
scheme is as follows (summarized in Table 1):
1. Benign
a. Low risk of malignancy
b. The diagnostic terms in this category include but are not
limited to nodular goiter, chronic lymphocytic thyroiditis,
hyperplastic/adenomatoid nodule in goiter and colloid
nodule.
c. Patients with a benign nodule are followed by clinical
and periodic radiologic examination and some patients
may undergo repeat FNA due to increase in the size of
nodule.
2. Follicular Lesion of Undetermined Significance/Aty-
pia of Undetermined Significance
a. Risk of malignancy 5–10%.
b. This is a heterogeneous category that includes cases in
which the cytologic findings are not convincingly benign,
yet the degree of cellular or architectural atypia is not suf-
ficient for an interpretation of "Follicular Neoplasm" or
"Suspicious for Malignancy".
c. Some cases are placed in this category because of a com-
promised specimen (e.g. low cellularity, poor fixation,
obscuring blood).
d. This group can benefit from repeat FNA and correlation
with clinical and radiologic findings.
e. This category is optional and when utilized should ide-
ally represent less than 7% of all thyroid FNA interpreta-
tions.
Table 1: Accepted Thyroid FNA Classification Schemes
Suggested Categories Alternate Category (s) terms* Risk of Malignancy**
Benign <1%




Follicular Neoplasm Suspicious for follicular neoplasm 20–30%
Suspicious for Malignancy 50–75%
Malignant 100%
Non-diagnostic Unsatisfactory
*These terms can be used instead of the suggested category terms (based on website responses and NCI meeting attendees); ** Data collected 
from literature [71-73, 80, 98]CytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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3. Follicular-Neoplasm/Suspicious for Follicular Neo-
plasm
a. Low to intermediate risk of malignancy 20–30%.
b. This category applies to non-papillary  follicular pat-
terned lesions/neoplasms and Hurthle cell lesions/neo-
plasms. A majority of studies have shown that up to 20%
of the thyroid lesions classified as such are found to be
malignant on surgical excision (the predictive value/rela-
tive risk of this diagnosis can be included in the report).
This percentage may be higher in Hurthle cell lesions if
the nodule is equal to or larger than 3.5 cm in greatest
dimension.
c. Other suggested diagnostic terms for this category are
micro-follicular proliferation/lesion, suggestive of neo-
plasm and follicular lesion.
d. Most patients with this diagnosis will undergo lobec-
tomy/hemithyroidectomy and a definite diagnosis (ade-
nomatoid nodule vs. adenoma vs. carcinoma) is rendered
on surgical pathology examination.
e. Some laboratories prefer the term "Suspicious for Follic-
ular Neoplasm" may also be used for its clarity and for
risk-management reasons.
4. Suspicious for Malignancy
a. This term can be used as:
i. Suspicious for papillary carcinoma (a majority of cases
in this group (50–75%) are found to be follicular variant
of papillary carcinoma).
ii. Suspicious for medullary carcinoma (applies to cases in
which there is limited specimen to perform confirmatory
immunostains for calcitonin. The cytology report should
include a recommendation to assay serum calcitonin lev-
els to confirm cytologic impression).
iii. Suspicious for other primary and secondary malignan-
cies
iv. Suspicious for neoplasm because of total necrosis of
the lesional cells (anaplastic carcinoma).
5. Malignant
6. Non-diagnostic
a. Specimen processed and examined, but non-diagnostic
due to limited cellularity, no follicular cells or poor fixa-
tion and preservation. A repeat FNA can be recommended
in these cases (see discussion on Post-FNA Testing and
Treatment Options).
B. Morphologic Criteria
1. Morphologic criteria of benign, non-neoplastic conditions
Nodular Goiter: The cytology specimen from a goiterous
nodule (depending upon the preparation method) is
characterized by:
• Abundant watery colloid (usually appears bluish-pink
magenta in color and shows a "chicken wire" artifact due
to air-drying in smears stained with Romanowsky stain).
• Follicular cells appear small, round to oval in shape with
dark nuclei and are arranged in monolayer sheets, groups
with follicle formation or as single cells[76,77]. Macro-
phages, usually filled with hemosiderin granules are also
noted; however, their number depends upon the presence
or absence of degenerative changes or a cystic component
[77].
Autoimmune Thyroiditis/Chronic Lymphocytic Thyroiditis/
Hashimoto's Thyroiditis
The FNA is usually performed in patients with thyroiditis
who present with distinct nodules that are cold on thyroid
scan. [78]The specimens from such cases usually show:
• Scant colloid, Hürthle cells, follicular cells, lymphocytes
and few plasma cells.
• The lymphocytes are usually seen in the background,
percolating between cell groups and in some cases one
may see an intact lymphoid follicle. The Hürthle cells may
display nuclear atypia and similarly follicular cells may
show some chromatin clearing and nuclear grooves; how-
ever, one should refrain from interpreting these changes
as malignant [78].
• An extensive lymphocytic infiltrate can appear monoto-
nous and mistaken for malignant lymphoma arising in
lymphocytic thyroiditis [78,79]. If one suspects lym-
phoma it is advisable that an aliquot of specimen be sub-
mitted for flow cytometry to confirm the morphologic
suspicion.
2. Morphologic criteria of follicular-patterned lesions
• Fine-needle aspiration (FNA) is a screening test for fol-
licular patterned lesions of the thyroid because it cannot
distinguish between benign and malignant non-papillary
follicular and Hurthle cell lesions. The cytopathologists
often struggle with the diagnosis of follicular patterned
lesions due to the lack of well-defined cytomorphologic
criteria (both benign and malignant lesions appear simi-
lar in cytologic specimens) and standardized terminology
[80,81]. This is further complicated by the lack of "meet-CytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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ing of minds" in the histologic diagnosis of these lesions
[82]. To rely on cytologic atypia in follicular and Hürthle
cells to differentiate between benign and malignant
lesions has not proven to be a reproducible criterion [83].
A number of benign conditions such as thyroiditis, post
treatment effects and adenomatoid nodules can show
marked cellular atypia [78,79].
Follicular lesion of undetermined significance/atypia of undetermined 
significance
FNA specimens in this category include cases that partly
display features of both hyperplastic/adenomatoid nod-
ules and follicular neoplasm i.e. cellular specimen show-
ing follicular cells arranged in cohesive groups and
microfollicles with focal nuclear crowding and overlap-
ping and monolayer sheets in a background of watery col-
loid admixed with thick colloid and few macrophages.
The question arises as to how useful it may be to divide
non-papillary follicular lesions into two separate catego-
ries; should all be diagnosed as indeterminate follicular
lesions with the decision of how to manage being left to
the clinician via either clinical follow-up and repeat FNA
or surgical excision. Repeat FNA has been shown to play
an important role in the management of thyroid nodules.
Published experiences have shown that by repeating the
FNA >50% of nodules which are non-diagnostic or inde-
terminate on initial cytologic diagnosis can latter be
placed into definite diagnostic categories with repeat FNA
[71,73].
Follicular neoplasm/Suspicious for follicular neoplasm
This term encompasses both benign and malignant
tumors; i.e. follicular adenoma and carcinoma. The FNA
of a follicular neoplasm usually shows:
• Hypercellularity as compared to most aspirates of nodu-
lar goiter demonstrating a monotonous population of fol-
licular cells with minimal or absent background colloid.
The cells are usually arranged in three dimensional groups
and microfollicles with prominent nuclear overlapping
and crowding. Some cases may show nuclear atypia; how-
ever, this is not a diagnostic criterion of malignancy, since
benign nodules can also show nuclear atypia [84].
• The presence of microfollicles in an FNA specimens may
be diagnostic of a follicular lesions neoplasm (adenoma
or carcinoma) [85]. Some authors have proposed the term
micro-follicular lesion [75]. However, various studies have
shown that the interpretation of microfollicles suffers
from inter-observer variability. Additionally, aspirates of
normal thyroid and hyperplastic/adenomatoid nodules
can show microfollicles [86]. Others have suggested that
diagnosis of follicular neoplasm should only be used
when a thyroid FNA specimen demonstrates a monoto-
nous cell population arranged in cohesive groups with
nuclear overlapping and crowding in a background if
thick instead of watery colloid [80].
Hurthle cell neoplasm
FNA specimens of Hürthle cell lesions (benign and malig-
nant) usually show:
• Cellular aspirate comprising a single cell population of
Hürthle cell in a background of minimal colloid. Cells can
be arranged in monolayer sheets, follicular groups or as
scattered single cells [87]. Some authors have suggested
that cellular dispersion leading to single cells is more
common in aspirates of Hurthle cell carcinoma than ade-
noma; however, this observation has not been validated
[87]. Cellular atypia is also commonly observed in
Hurthle cell lesion; this can be seen in the form of random
nuclear enlargement, multi-nucleation, cellular pleomor-
phism and prominent nucleoli.
• FNA specimens of neoplastic Hurthle cell lesions may
show intra-cytoplasmic lumens and transgressing vessels
[88].
Follicular Variant of Papillary Carcinoma
Similar to the histologic diagnosis the cytologic interpre-
tation of FVPTC can also be difficult. The FNA specimens
of FVPTC usually show:
• Tumor cells arranged in monolayer sheets and follicular
groups in a background of thin colloid. Thick colloid can
also be present, however, much less as compared to classic
PTC. The tumor cells show nuclear elongation, chromatin
clearing and thick nuclear membranes; however, nuclear
grooves and inclusions are rare. Nonetheless, chromatin
clearing and nuclear membrane thickening is always seen
in these cases [89,90].
• If a thyroid FNA specimen focally shows cells with
nuclear elongation, chromatin clearing and grooves but
lacks nuclear inclusions, it may be diagnosed such as "fol-
licular neoplasm with features suspicious for PTC.
3. Morphologic Criteria of Malignant Tumors
The well-differentiated thyroid carcinomas are the com-
monest form of malignant thyroid tumors. They are more
common in young adults, whereas, the less differentiated
and anaplastic tumors of the thyroid are prevalent in older
age.
Cytology of Papillary Thyroid Carcinoma (PTC) and its variants
The cytologic features of PTC can be divided into major
and minor diagnostic features; these are as follows:
• Major Diagnostic Criteria: Enlarged, oval "and irregu-
lar" nucleus, eccentric and often multiple micro-nucleoli,CytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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fine, pale chromatin, longitudinal intranuclear grooves
and intranuclear pseudo-inclusions [76,91].
• Minor Diagnostic Criteria: Papillary cyto-architecture,
syncytial monolayers, dense squamoid cytoplasm, "Bub-
ble gum" colloid, psammoma bodies, multinucleated
giant cells, histiocytoid cells and cellular swirls [92-94].
Follicular variant of papillary carcinoma: Refer to sec-
tion on follicular patterned lesions of thyroid.
Tall cell variant of papillary carcinoma
Cytology specimens of this tumor usually show elongated
cells with sharp cytoplasmic borders, granular eosi-
nophilic cytoplasm and variably sized nuclei with nuclear
features of papillary carcinoma. The nuclear features of
papillary carcinoma are usually abundant and readily
identifiable as compared to other variant of PTC [95].
Medullary Thyroid Carcinoma
The FNA specimens from MTC can show varied morpho-
logic pattern similar to that seen in surgical pathology
specimens. The majority of MTC cases show:
• A cellular aspirate consisting of round to oval cells
arranged mainly as single cells or loosely cohesive groups.
The individual tumor cells show abundant eosinophilic
granular cytoplasm and up to 20% of cells will demon-
strate fine granules in Romanowsky-stained preparations.
The nuclei are usually eccentric giving rise to a plasmacy-
toid appearance to tumor cells.
• The nuclear chromatin is similar to that seen in neuroen-
docrine tumors; salt and pepper type with inconspicuous
nucleoli. Intranuclear inclusions and multinucleated cells
can also be seen.
• In some cases of MTC the tumor cells are can assume a
"spindle shape" and appear mesenchymal in origin. Amy-
loid may be observed as acellular material in the form of
strings or as round to oval shaped fragments.
• In cytology specimens the diagnosis of MTC can be con-
firmed by performing immunostains for Calcitonin. In
cases with limited cellularity it is advisable to have a
serum Calcitonin levels performed on the patient to con-
firm the diagnosis of MTC [76,96].
Anaplastic carcinoma
The aspirates from anaplastic carcinoma usually do not
pose any diagnostic difficulties; they can be readily classi-
fied as malignant due to extreme cellular pleomorphism
and obvious malignant features [97,98].
V. Utilization of Ancillary Studies in Thyroid 
FNA
A. Indications for ancillary studies in thyroid FNA
Medullary carcinoma and anaplastic carcinoma are the
most common primary thyroid tumors that may require
additional immunohistochemical studies to confirm the
diagnosis. Although rare, metastatic tumors may occur in
the thyroid and a history of a known primary along with
a pertinent immunohistochemical panel would be help-
ful in making a final diagnosis. The utilization of ancillary
studies to re-classify an indeterminate or suspicious FNA
into a benign or malignant category or to refine the risk of
malignancy within this category is controversial.
B. Specific ancillary studies to be performed for each of 
these indications
The ancillary studies with the widest utility involve the
detection of specific proteins using immunologic tech-
niques, typically immunohistochemistry on cell block
preparations. Immunocytochemistry may also be utilized
but only after careful validation of the protocols for this
type of specimen. In cases of suspected medullary carci-
noma, an immunohistochemical panel of calcitonin, thy-
roglobulin, CEA, and chromogranin can be confirmatory.
Immunohistochemical findings should be correlated with
serum calcitonin levels, particularly if there is insufficient
FNA sample for ancillary studies [99-106]. Care should be
employed in evaluating the results of calcitonin staining
on cell block preparations of thyroid neoplasms with
oncocytic features as cases of non-specific staining of
oncocytic cells have been documented. Endogenous
biotin in follicular cells may also cause non-specific stain-
ing.
Anaplastic carcinoma is often apparent based on its pleo-
morphic cytomorphology and aggressive clinical presen-
tation. Anaplastic carcinoma often lacks TTF-1 and
thyroglobulin staining. However, IHC for pan-cytokeratin
may be utilized to distinguish anaplastic carcinoma from
sarcomas. The clinical setting may also raise the possibil-
ity of a metastatic lesion [107-112]. The most common
metastases to the thyroid arise from primary carcinomas
of the kidney, lung, breast, colon, or malignant
melanoma. The clinical history and presentation is impor-
tant in determining the appropriate ancillary studies. One
may initially employ TTF-1 and thyroglobulin IHC to nar-
row the primary site to thyroid, followed by further IHC
characterization if these stains are negative [113].
One challenging area is excluding the possibility of lym-
phoma in the setting of Hashimoto's thyroiditis. All cases
of Hashimoto's thyroiditis should not be automatically
sent for flow cytometric immunophenotyping. In addi-
tion, immunophenotyping results from thyroid FNA sam-
ples should be interpreted with caution sinceCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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Hashimoto's thyroiditis may yield κ/λ ratios that are
skewed beyond normal values associated with reactive
lymph nodes [114]. The indication for flow cytometric
immunophenotyping should be based on cytomorpho-
logic or clinical features that raise the suspicion of lym-
phoma. Parathyroid tissue can be extremely difficult to
distinguish from thyroid tissue based on cytomorpho-
logic features alone. In this setting, IHC for TTF-1, PTH,
and chromogranin may be helpful. Neither the IHC nor
the cytomorphology should be utilized to distinguish nor-
mal from abnormal parathyroid tissue. Chemical detec-
tion of PTH levels in FNA samples has been utilized, and
may be considered following careful assay validation
[115-120]. The identification of metastatic thyroid carci-
noma to a lymph node in patients with a known history
of thyroid carcinoma is often straightforward based on
cytologic features. In challenging cases, IHC for TTF-1, cal-
citonin, and thyroglobulin may be useful in identifying
the thyroid as a primary site for the nodal metastasis. Sev-
eral studies have addressed the utilization of chemical
assays for thyroglobulin on the FNA sample from neck
lymph nodes [121,122]. Such an approach should be
implemented with caution since clinical management of
patients with benign or indeterminate lymph node FNAs
containing detectable thyroglobulin remains undefined.
Ancillary studies that would permit re-classification of an
indeterminate or suspicious thyroid FNAs into a benign or
malignant category are highly desirable. Potential thyroid
carcinoma-associated molecular markers include proteins
(galectin-3, Cytokeratin-19, HBME-1), chromosomal
translocations (RET/PTC,  PAX8/PPARG), and genetic
mutations (BRAF,  RAS) [123-125]. This review has
focused on molecular markers that have proven efficacy
for the above stated indication. The specificity of several
markers for thyroid carcinoma is promising, but based on
current limited evidence, widespread clinical use will
require further studies.
The indications for performing ancillary studies and the
current state of the science for ancillary studies in thyroid
FNA are summarized in Table 2.
C. Sample preparation for each type of ancillary study
If IHC is anticipated, one dedicated pass should be per-
formed for cell block preparation from an FNA sample.
The routine use of thyroid core biopsy to perform IHC is
not supported. If lymphoma is suspected, at least one ded-
icated pass in a supportive medium should be obtained
for flow cytometric analysis. Ancillary studies to detect
genetic alterations may require dedicated passes and spe-
cial processing protocols depending on the analyte (DNA
or RNA) and the methodology (FISH, PCR, RT-PCR).
VI. Post FNA Options for Testing and 
Treatment
A. Follow-up of "Non-diagnostic" FNA Results
A universally accepted approach to "Non-diagnostic" thy-
roid FNAs is currently lacking. The strategy reviewed here
is based on the American Thyroid Association's proposal,
recent literature and the NCI Conference on Thyroid FNA
[9,48]. Non-diagnostic aspirates obtained from cystic and
solid nodules are treated differently in follow-up strate-
gies. Aspirates composed of pure colloid and lacking a cel-
lular component are considered benign, but require close
clinical and ultrasound follow-up. Aspirates of cysts con-
taining blood and histiocytes but no epithelial compo-
nent need correlation with ultrasound findings [19].
Many cystic nodules contain only colloid surrounded by
a thin rim of benign epithelium. These cysts are at very
low risk for harboring malignancy. Many authors recom-
mend these cysts be managed by nonsurgical follow-up.
Other authors point to the low, but real incidence of pap-
Table 2: Review of Utilization of Ancillary Studies in Thyroid FNA
Suspected medullary carcinoma
• IHC panel (calcitonin, thyroglobulin, CEA, chromogranin)
• Serum calcitonin
Suspected anaplastic carcinoma
• IHC for pan-cytokeratin
Suspected metastatic carcinoma
• IHC for TTF-1 (If TTF-1 negative, then expand IHC panel based on cytomorphology and clinical setting to identify primary)
Suspected lymphoma
• Flow cytometric immunophenotyping
Suspected parathyroid lesion
• IHC for TTF-1, PTH, chromogranin
• May consider PTH level assessment on FNA sample
Suspected metastatic thyroid carcinoma to lymph node
• IHC for TTF-1, thyroglobulin, calcitonin
• May consider thyroglobulin level assessment on FNA sample
Atypical/Borderline/Suspicious FNA
• No specific tests based on insufficient evidenceCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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illary carcinoma in cysts and recommend surgical resec-
tion after two "Non-diagnostic" aspirations. The timing of
repeat needle aspiration has not been established, but 6 to
18 months appears reasonable.
Cystic lesions with a "Non-diagnostic" aspirate should
undergo repeat FNA if ultrasound demonstrates suspi-
cious areas [12,126]. The repeat FNA should be under
ultrasound guidance and, when possible, intraprocedural
review of the aspirated material by a cytopathologist is
recommended [48,19]. When repeat FNA yields "Non-
diagnostic" material, correlation with family history, close
clinical and ultrasonographic follow-up is suggested [19].
Solid nodules with a "Non-diagnostic" aspirate should be
re-aspirated with ultrasound guidance with, if possible,
intraprocedural review by a cytopathologist. If repeat
smears are "Non-diagnostic," surgery ought to be consid-
ered. If the patient is likely to return for follow-up and the
nodule is 1 cm or less in size, close clinical follow-up with
ultrasound examination is a reasonable alternative to sur-
gery [19]. When growth of the nodule is detected during
surveillance, excision is suggested but repeat FNA is an
acceptable approach. In general, for both solid and cystic
"Non-diagnostic" aspirates a waiting period of at least
three months should elapse between the initial "Non-
diagnostic" aspirate and reaspiration. If suspicion for car-
cinoma is high based on clinical or ultrasonographic find-
ings, a shorter waiting period may be appropriate.
B. Follow-up of "Benign" FNA Results
Management of patients with a "Benign" FNA diagnosis
has varied between institutions. Because cytologically
benign thyroid nodules are associated with up to 5% false
negatives, these nodules require careful follow-up
[16,127]. Patients with multiple thyroid nodules have the
same risk of malignancy as those with a single nodule.
Follow-up of patients with multiple nodules should be
the same as those with a solitary nodule. Certain ultra-
sonographic characteristics (microcalcification, hypoe-
chogenicity, intranodular hypervascularity) indicate a
higher likelihood of malignancy [12,126]. Nodules with
these features require more frequent clinical and ultra-
sonographic follow-up after a benign FNA. The false neg-
ative rate may be higher when FNAs are directed by
palpation rather than by ultrasound [17,128,129]. Thus,
palpation directed FNAs may require closer follow-up.
Medical suppressive therapy to confirm a benign cytologic
diagnosis remains controversial. Multiple randomized tri-
als have shown that thyroid hormone suppression may
result in a decrease in nodule size in patient populations
with borderline low iodine intake. The data are less con-
vincing for populations ingesting sufficient iodine [130-
132]. Rare examples of carcinomas suppressed by thyroid
hormone have been reported. It is unclear that thyroid
suppressive therapy is a reliable test for confirmation of a
benign cytologic diagnosis of a solitary nodule.
Cytologically benign nodules can be followed clinically
with interval ultrasound examination [19]. Benign nod-
ules may be reaspirated or surgically removed when sig-
nificant changes occur in their ultrasonographic
appearance. Ultrasonography appears to be the best tech-
nique for detection of changes in nodule size[133]. There
is no general agreement as to what constitutes a significant
increase in nodule size. The American Thyroid Association
(ATA) has suggested that a 20% increase in nodule diam-
eter with a minimum increase in two or more dimensions
of at least 2 mm is a reasonable definition for a significant
change in nodule size [9]. The ATA has also recommended
clinical follow-up of cytologically benign and easily pal-
pable nodules occur at 6–18 month intervals. When nod-
ules are not easily palpable, the recommendation is for
serial ultrasound examinations at 6–18 month intervals
[9].
Thyroid nodules cytologically diagnosed as benign
require careful clinical follow-up. Easily palpable nodules
may be followed clinically at 6–18 month intervals. Nod-
ules which are not easily palpable should receive serial
ultrasound examinations at 6–18 month intervals. The
total duration of the follow-up period should be at least
3–5 years. When a 20% increase in nodule diameter or a
minimum of 2 mm increase in two dimensions is
detected, repeat FNA is performed. Repeat FNA should be
performed if ultrasound abnormalities (irregular margins,
central hypervascularization) develop. The repeat FNA
should be under ultrasound guidance. Attendance of a
pathologist at reaspiration is desirable. At this time, hor-
mone suppressive therapy can not be recommended as a
diagnostic maneuver for confirmation of benignity in a
cytologically benign thyroid nodule. Ethanol ablation
may be considered in selected patients.
C. Follow-up of FNA specimens diagnosed as "Follicular 
lesion/Atypical/Borderline"
A variety of terms are employed to convey uncertainty
about the significance of some thyroid cytologic findings.
Such changes do not rise to the level of a significant con-
cern for a follicular neoplasm meriting lobectomy (see
section D), nor do they fit a "Suspicious for Malignancy"
interpretation. Because of cytologic or architectural atypia,
neither can such cases be reliably called benign. A variety
of diagnostic headings are used for such cases including
"Atypical Follicular Lesion", "Cellular Follicular Lesion"
and "Indeterminate" [73,134]. The term "Atypical/Bor-
derline" will be used for this discussion. Approximately
5–10% of the "Atypical/Borderline" category are malig-
nant neoplasms. Given that this diagnostic category isCytoJournal 2008, 5:6 http://www.cytojournal.com/content/5/1/6
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associated with low specificity and a low positive predic-
tive value, the appropriate follow-up for this category
remains controversial. Some authorities have recom-
mended repeat FNAs, repeat ultrasound scans, or repeat
radio-nucleotide uptake studies. A repeat FNA is benign in
about one-half of patients, obviating the need for surgery
[71]. Radiological correlation may aid in improving the
overall positive predictive value of this category. Besides
increasing size, ultrasonographic features such as hypoe-
chogenicity, irregular border, calcifications and abnor-
malities of vascularization all favor a malignant diagnosis
[54,135].
Outside expert cytopathology consultation may be con-
sidered in cases with an "Atypical/Borderline" cytologic
diagnosis. In general, a conservative approach may be
taken. After a single "Atypical/Borderline' interpretation, a
repeat FNA should be considered in 3 to 6 months. If the
repeat FNA is "Atypical/Borderline" or worse, a surgical
consultation should be considered [71].
D. Follow-up of an FNA with the diagnosis of "Neoplasm 
(Follicular)"
This category has, in some reports, been termed "Suspi-
cious for Follicular Neoplasm" [54,71]. The majority of
cases in this category are adenomas, but 20 to 30% are car-
cinomas [73]. Patients with a diagnosis of "Follicular
Neoplasm" should be referred for operative exploration.
Usually a lobectomy is performed followed by histologic
examination for capsular and vascular invasion.
The utility of frozen section evaluation for capsular or vas-
cular invasion is controversial. Most participants at the
NCI Meeting voiced the opinion that frozen section eval-
uation does not play a role in the separation of follicular
adenoma from follicular carcinoma. Some surgeons may
perform frozen section to determine the necessity for
additional surgery, but there is no published data to sup-
port this practice. When frozen section is not utilized, ini-
tial surgery is lobectomy. If subsequent histologic
examination discloses capsular or vascular invasion, the
diagnosis of follicular carcinoma is made. Depending on
the surgeon's discretion, histopathologic findings and
clinical status of the patient reoperation with thyroidec-
tomy may be performed.
E. Follow-up of FNAs with a diagnosis of "Suspicious for 
Malignancy"
Approximately 50–75% of lesions cytologically diag-
nosed as "Suspicious for Malignancy" are papillary carci-
nomas [71,73,134]. Less commonly, other malignancies
such as medullary carcinoma are included in this category.
Patients with an FNA diagnosis of "Suspicious for Malig-
nancy" should be referred for thyroid lobectomy. Subse-
quent operative intervention depends on histological
review.
F. Follow-up of "Malignant" FNA Results
This category refers to the histopathologic entities of pap-
illary carcinoma, medullary carcinoma, lymphoma and
anaplastic carcinoma. A comprehensive review of this
subject concluded that the cytologic diagnosis of malig-
nancy in a thyroid nodule should result in surgical consul-
tation. Whenever possible, the type of carcinoma present
should be stated in the cytology report. If a metastatic car-
cinoma is suspected, clinical and imaging studies should
be undertaken to establish the primary site. At the sur-
geon's discretion, surgical intervention may initially be
simple lobectomy or intraoperative frozen section exami-
nation to determine if total thyroidectomy should be per-
formed. If frozen section is equivocal, the operative
procedure is ended with lobectomy and further therapy is
based on permanent sections. Depending on the sur-
geon's discretion and the characteristics of the malig-
nancy, total thyroidectomy may be performed for a
cytological diagnosis of papillary carcinoma. Controversy
exists as to whether total thyroidectomy or unilateral
lobectomy should be performed for papillary carcinoma.
The selection of lobectomy versus thyroidectomy depends
on the evaluation of the patient's clinical status and the
size and nature of the papillary carcinoma. Total thyroid-
ectomy may be accompanied by a central compartment
dissection. For patients with large, bulky disease or recur-
rent laryngeal nerve dysfunction, preoperative cross sec-
tional imaging should be considered as well as ultrasound
imaging for lateral neck nodal disease.
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